Knowledge structure and emerging trends of AR variants in prostate cancer: a bibliometric analysis based on CiteSpace and VOSviewer

Prostate cancer is a common malignancy in urology which often develops into castration-resistant prostate cancer (CRPC) after hormone therapy. Studies have shown that the mechanism of its occurrence is related to androgen receptor splice variants (AR splice variants). This work employs a bibliometric approach to explore the knowledge structure and emerging trends of AR variants in prostate cancer. The literature from 2000 to 2021 was obtained from Web of Science Core Collection (WoSCC), and the results were analyzed and visualized via CiteSpace and VOSviewer regarding publication number, citation number, country, region, institution, journal, author, keyword and reference. A total of 1503 publications were obtained. The number of publications and citations in this field is increasing. United States is the most prominent country, and University of Washington is the most influential institution in terms of this research field. European Urology is the most authoritative journal regarding this field. Gleave, Martin is the most productive author, and collaborated closely with others having centrality >0.1. The keywords abiraterone and AR-V7 have the strongest citation bursts in recent years and continuing to the end of 2021 which indicate the trend and further research directions. The most cited papers and co-cited references were related to the clinical significance of AR-V7 and its mechanism of promoting CRPC. This study used visualization software CiteSpace and VOSviewer to analyze the current status and the research trends of AR variants in prostate cancer (PCa) over the past 20 years. The findings can identify research hotspots and reveal future research directions.

Prostate cancer; Androgen receptor splice variant; CiteSpace; VOSviewer; Bibliometric analysis

[1] Chen S, Jian T, Chi C, Liang Y, Liang X, Yu Y, et al. Machine learning-based models enhance the prediction of prostate cancer. Frontiers in Oncology. 2022; 12: 941349.

[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020; 70: 7–30.

[3] Crona DJ, Whang YE. Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance. Cancers. 2017; 9: 67.

[4] Wang BR, Chen YA, Kao WH, Lai CH, Lin H, Hsieh JT. Developing new treatment options for castration-resistant prostate cancer and recurrent disease. Biomedicines. 2022; 10: 1872.

[5] Lu C, Luo J. Decoding the androgen receptor splice variants. Transla-tional Andrology and Urology. 2013; 2: 178–186.

[6] Kushwaha PP, Gupta S. New insights for drug resistance in metastatic castration-resistant prostate cancer. Cancer Drug Resistance. 2022; 5: 846- 849.

[7] Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England Journal of Medicine. 2014; 371: 1028–1038.

[8] Sribudiani Y, Marwan DW, Aulanni’am A, Widodo MA, Purnomo BB, Panigoro R, et al. Germline mutations and polymorphisms of androgen receptor in prostate cancer patients: frequency and results of in silico analysis. Asian Pacific Journal of Cancer Prevention. 2018; 19: 2241–2245.

[9] Lu J, der Steen TV, Tindall DJ. Are androgen receptor variants a substitute for the full-length receptor? Nature Reviews Urology. 2015; 12: 137–144.

[10] Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Research. 2009; 69: 2305–2313.

[11] Sun S, Sprenger CCT, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. The Journal of Clinical Investigation. 2010; 120: 2715–2730.

[12] Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proceedings of the National Academy of Sciences. 2010; 107: 16759–16765.

[13] Chi KN, Thomas S, Agarwal N, Feng F, Attard G, Wyatt AW, et al. 883P—androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN. Annals of Oncology. 2019; 30: v347–v348.

[14] Huang L, Xu G, He J, Tian H, Zhou Z, Huang F, et al. Bibliometric analysis of functional magnetic resonance imaging studies on acupuncture analgesia over the past 20 years. Journal of Pain Research. 2021; 14: 3773–3789.

[15] Lv Z, Wang X, Zhu C, Wang K. The global status of research in prostate cancer bone metastasis: a bibliometric and visualized analysis. Frontiers in Medicine. 2022; 9: 931422.

[16] Zhang Z, Zhu Y, Wang Q, Chang T, Liu C, Zhu Y, et al. Global trends and research hotspots of exercise for intervening diabetes: a bibliometric analysis. Frontiers in Public Health. 2022; 10: 902825.

[17] Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, et al. Concordance of Circulating Tumor DNA and matched metastatic tissue biopsy in prostate cancer. Journal of the National Cancer Institute. 2017; 109: djx118.

[18] Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Research. 2013; 73: 483–489.

[19] Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Annals of Oncology. 2015; 26: 1859–1865.

[20] Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, et al. Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Reports. 2020; 31: 107669.

[21] Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, et al. LuCaP 35: a new model of prostate cancer progression to androgen independence. The Prostate. 2003; 55: 239–246.

[22] Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, et al. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clinical Cancer Research. 2014; 20: 1590–1600.

[23] Ferraldeschi R, Welti J, Luo J, Attard G, de Bono JS. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene. 2015; 34: 1745–1757.

[24] Cucchiara V, Cooperberg MR, Dall’Era M, Lin DW, Montorsi F, Schalken JA, et al. Genomic markers in prostate cancer decision making. European Urology. 2018; 73: 572–582.

[25] Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Research. 2009; 69: 16–22.

[26] Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nature Reviews Cancer. 2015; 15: 701–711.

[27] Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis. 2000; 21: 427–433.

[28] Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017; 355: 78–83.

[29] Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015; 349: 1351–1356.

[30] Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncology. 2015; 1: 582–591.

[31] Scher HI, Fizazi K, Saad F, Taplin M, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine. 2012; 367: 1187–1197.

[32] Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Research. 2012; 72: 3457–3462.

[33] Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research. 2008; 68: 5469–5477.

[34] Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KAT, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Research. 2013; 73: 483–489.

[35] de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. The New England Journal of Medicine. 2011; 364: 1995–2005.

[36] Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. Journal of Clinical Oncology. 2017; 35: 2149–2156.

[37] Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. The Journal of Clinical Investigation. 2019; 129: 192–208.

[38] Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. Journal of Clinical Oncology. 2019; 37: 1120–1129.

[39] Scher HI, Graf RP, Schreiber NA, Jayaram A, Winquist E, McLaughlin B, et al. Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer. JAMA Oncology. 2018; 4: 1179–1186.

[40] Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences. 2019; 116: 11428–11436.

[41] Jian T, Zhan Y, Hu K, He L, Chen S, Hu R, et al. Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Frontiers in Pharmacology. 2022; 13: 955925.

[42] Liu X, Yu C, Bi Y, Zhang ZJ. Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China. Public Health. 2019; 172: 70–80.

[43] He Y, Lu J, Ye Z, Hao S, Wang L, Kohli M, et al. Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. Nucleic Acids Research. 2018; 46: 1895–1911.

[44] Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proceedings of the National Academy of Sciences. 2004; 101: 5303–5310.

[45] Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology. 2008; 26: 4563–4571.

[46] Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England Journal of Medicine. 2013; 368: 138–148.

[47] Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, et al. Resistance to CYP17a1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clinical Cancer Research. 2011; 17: 5913–5925.

[48] Lu J, Lonergan PE, Nacusi LP, Wang L, Schmidt LJ, Sun Z, et al. The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. The Journal of Urology. 2015; 193: 690–698.

[49] Serrano MJ, Garrido-Navas MC, Diaz Mochon JJ, Cristofanilli M, Gil-Bazo I, Pauwels P, et al. Precision prevention and cancer interception: the new challenges of liquid biopsy. Cancer Discovery. 2020; 10: 1635–1644.

[50] De Laere B, van Dam P, Whitington T, Mayrhofer M, Diaz EH, Van den Eynden G, et al. Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel Intra-AR structural variation and splice variant expression patterns. European Urology. 2017; 72: 192–200.

[51] Qu F, Xie W, Nakabayashi M, Zhang H, Jeong SH, Wang X, et al. Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clinical Cancer Research. 2017; 23: 726–734.

[52] Khan T, Becker TM, Scott KF, Descallar J, de Souza P, Chua W, et al. Prognostic and predictive value of liquid biopsy-derived androgen receptor variant 7 (AR-V7) in prostate cancer: a systematic review and meta-analysis. Frontiers in Oncology. 2022; 12: 868031.

[53] Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences. 2019; 116: 11428–11436.